WHO-Standard Factory Opens in Nigeria, Backed by FCMB and BoI

Sam Pharmaceuticals has commissioned a WHO-standard manufacturing facility in Nigeria, backed by financing from First City Monument Bank (FCMB) and the Bank of Industry (BoI), marking a concrete step in the country's effort to reduce dependence on imported medicines and raise the baseline for GMP compliance in sub-Saharan Africa. For quality and regulatory professionals tracking emerging market supply chain resilience, the development signals that frontier markets are beginning to align local manufacturing infrastructure with internationally recognised quality benchmarks.

Nigeria has long been identified as a high-priority market for local pharmaceutical production, given its population scale and historically high import dependency. A facility built to WHO Good Manufacturing Practice standards introduces a quality floor that has direct implications for procurement decisions by international health bodies, including UNICEF and the Global Fund, which require WHO prequalification or equivalent GMP certification as a condition of supply contracts. Plant heads and QA directors operating in the region will recognise that meeting WHO-GMP is not a ceiling but an entry point for participation in regulated tender markets.

The involvement of FCMB and BoI as financing partners reflects a broader pattern of development finance institutions and commercial banks structuring credit facilities around pharmaceutical sector growth in Nigeria. The Bank of Industry has previously positioned pharmaceutical manufacturing as one of its priority lending sectors within critical areas of the economy, a framing echoed by statements attributed to the Managing Director in connection with this facility. Sam Pharmaceuticals Chairman and Chief Executive Officer has been identified as a principal figure in the project, though detailed process validation scope, dosage form capabilities, and facility square footage have not been disclosed in available source material.

Source: This article is based on reporting by Pharmaceutical Industry News (EIN Presswire, published 27 April 2026). The source article contained limited technical and operational detail. Pharma Now will update this report as additional facility specifications and regulatory filing information become available.